Krystal Biotech, Inc.
KRYS
$306.29
-$10.01-3.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 81.53% | 129.74% | 279.80% | 38.50% | 116.86% |
| Total Depreciation and Amortization | -19.25% | -24.83% | -45.64% | -50.83% | -26.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.80% | -33.99% | -36.15% | 180.70% | 175.56% |
| Change in Net Operating Assets | 80.15% | -151.91% | -48.13% | 91.19% | 4.23% |
| Cash from Operations | 80.70% | 62.75% | 178.16% | 1,267.39% | 396.20% |
| Capital Expenditure | -40.44% | -182.00% | -100.85% | -65.39% | -19.59% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -99.57% | -99.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.39% | 70.54% | -69.37% | -292.67% | -367.74% |
| Cash from Investing | 65.03% | 64.26% | -70.74% | -469.02% | -462.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54.81% | -30.06% | -71.16% | -78.76% | -91.76% |
| Repurchase of Common Stock | -21.97% | -159.12% | -158.69% | -158.60% | -158.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 170.16% | -67.78% | -116.66% | -113.10% | -98.13% |
| Foreign Exchange rate Adjustments | -156.54% | 162.45% | 8,325.00% | 431.65% | -807.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 483.28% | 1,224.85% | 2,470.76% | -88.50% | -123.02% |